Metronidazole Delayed-Release Capsules

For treating Clostridioides difficile

infection (CDI)

The company’s front-line product is a 505(b)(2) new formulation of a safe and traditional antibiotic, Metronidazole, for colon-specific delivery of the drug to combat a superbug, C. difficile, the leading cause of hospital-associated gastrointestinal illness,  responsible for ~ 500,000 infections and 29,000 deaths each year in the US. It places a high burden on the health-care system, $4.8 billion annually.